HBV Basics

This section is under development In the meantime, here are some resources that you can consult. HBV Pamphlet Foreign Language Pamphlets HBV Punjabi HBV Hindi   http://hcvadvocate.org/hepatitis/factsheetsB_pdf/ A_Basic_Guide_to_Hepatitis_B.pdf  

The Week in Review: June 1 – June 8, 2018

Friday, June 8, 2018 News Recap: Canada: New guidelines recommend hepatitis C screening be done for those born between 1945 and 1975. The Canadian Association for the Study of the Liver (CASL), a national group of health-care providers and researchers, published its guidelines on testing and treating hepatitis C in Monday's edition of the CMAJ. Canadians born between 1945 and 1975 – essentially the baby-boom generation – should be tested for the pot...

Findings could lead to treatment of hepatitis B

Researchers at the University of Delaware, working with colleagues at Indiana University, have gained new insights into the virus that causes hepatitis B -- a life-threatening and incurable infection that afflicts more than 250 million people worldwide. The discovery, which was published April 27 in the journal eLife, reveals previously unknown details about the capsid, or protein shell, that encloses the virus' genetic blueprint. Scientists believe th

The Week in Review: May 25 – June 1, 2018

Friday, June 1, 2018 News Recap: HCV: Large Study Confirms DAAs Protect Against HCC When Sustained Viral Response Achieved. Patients with hepatitis C virus who are successfully treated with direct-acting antiviral agents experience a dramatic reduction in their risk for liver cancer, new data show. However, the decrease is much lower for those diagnosed with cirrhosis before starting a DAA. HCV Guidance Updated for Screening and Treating Key Popu...

How Durable Is the Hepatitis B Vaccine?

About 85% of a cohort of Alaskans who received the hepatitis B vaccine at age 6 months or older showed evidence of protection after 35 years, although some may require a booster dose, according to a study presented at the 2017 Liver Meeting. “No chronic hepatitis B infections were identified in the cohort,” according to lead study author Michael Bruce, MD, MPH, an epidemiology team leader in the CDC’s Arctic Investigation Program Division of Preparedness

ContraVir Pharmaceuticals’ Cyclophilin Inhibitor, CRV431, Reduces Development and Progression of Liver Tumors in Preclinical Hepatocellular Carcinoma Study

EDISON, N.J., May 30, 2018 (GLOBE NEWSWIRE) -- ContraVir Pharmaceuticals Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development and commercialization of therapeutic drugs for the treatment of hepatitis B virus (HBV), announced today new findings confirming that CRV431, a cyclophilin inhibitor, reduces the number and size of liver tumors in a hepatocellular carcinoma (HCC) mouse model. Data from the study indicate that CRV431 reduced th

The Week in Review: April 28 – May 11, 2018

Friday, May 11, 2018 News Recap: HBV: CADTH recommends that tenofovir alafenamide (TAF) be reimbursed for the treatment of chronic hepatitis B. The CADTH Canadian Drug Expert Committee (CDEC) recommends that tenofovir alafenamide (TAF) be reimbursed for the treatment of chronic hepatitis B in adults with compensated liver disease, if the following condition is met: CONDITION: The drug plan cost of TAF should not exceed that of the lowest-cost prepar...

BRIEF: CADTH recommends that tenofovir alafenamide (TAF) be reimbursed for the treatment of chronic hepatitis B

IN BRIEF: RECOMMENDATION The CADTH Canadian Drug Expert Committee (CDEC) recommends that tenofovir alafenamide (TAF) be reimbursed for the treatment of chronic hepatitis B in adults with compensated liver disease, if the following condition is met: CONDITION: The drug plan cost of TAF should not exceed that of the lowest-cost preparation of tenofovir disoproxil fumarate (TDF). Read more: https://www.cadth.ca/tenofovir-alafenamide  

This Common Viral Disease Has Plagued Humanity Thousands of Years Longer Than We Thought

Evidence of Hepatitis B has been found in human DNA dating back to the Bronze Age, around 4,500 years ago. We now have proof that it infected humans broadly across Eurasia for millennia, pushing back the earliest evidence we have by thousands of years. Previously, the earliest evidence of Hepatitis B was just 450 years old - and its discovery in a mummified medieval Italian child was only announced earlier this year. A team led by geneticist Eske Wille

The Week in Review: April 20 – April 27, 2018

Friday, April 27, 2018 News Recap: Warnings: Synthetic cannabinoids and Hepatitis A could be a fatal combination. On April 9, 2018, the Missouri Department of Health and Senior Services (DHSS) issued a news release – “Use of Synthetic Cannabinoids Linked to Severe Bleeding in the US,” informing the public about the national outbreak of bleeding illnesses among those consuming synthetic cannabinoids which appear to have been contaminated with a long-...